Skip to main content


Log in

Evaluation of Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgery

  • Original Scientific Report
  • Published:
World Journal of Surgery Aims and scope Submit manuscript



Intensive trimodality therapy is needed for locally advanced esophageal squamous cell carcinoma (ESCC). However, some patients develop recurrence and die of cancer even after trimodality therapy.


We evaluated prognostic factors based on data from 125 patients with ESCC who underwent neoadjuvant chemoradiotherapy (NCRT) comprising concurrent chemotherapy and 40 Gy of radiation, followed by curative-intent esophagectomy.


Thirty-four (27.2%) patients achieved a pathological complete response (pCR) after NCRT. The 5-year recurrence-free (RFS) and overall survival (OS) rates of all patients were 49.2 and 52.9%, respectively, and were significantly better for patients with pCR than without pCR (p = 0.01 and 0.02, respectively). Univariate and multivariate analyses selected performance status [PS 0 vs. 1: hazard ratio (HR) 2.05; 95% confidence interval (CI) 1.30–4.84; p = 0.01] and ypN (0 vs. 1: HR 2.33; 95% CI 1.12–4.84; p = 0.02; 0 vs. 2/3: HR 3.73; 95% CI 1.68–8.28; p = 0.001) as independent covariates for RFS. Furthermore, PS (0 vs. 1; HR 2.94; 95% CI 1.51–5.72; p = 0.002) and ypN (0 vs. 1; HR 2.26; 95% CI 1.09–4.69; p = 0.03; 0 vs. 2/3: HR 3.90; 95% CI 1.79–8.48; p = 0.001) were also independent covariates for OS.


Performance status 1 and ypN+ were significantly associated with a poor prognosis after trimodality therapy for ESCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others


  1. Sjoquist KM, Burmeister BH, Smithers BM, Australasian Gastro-Intestinal Trials Group et al (2011) Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 12:681–692

    Article  PubMed  Google Scholar 

  2. van Hagen P, Hulshof MC, van Lanschot JJ et al (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366:2074–2084

    Article  PubMed  Google Scholar 

  3. Tepper J, Krasna MJ, Niedzwiecki D et al (2008) Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 26:1086–1092

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Hamai Y, Hihara J, Emi M et al (2015) Results of neoadjuvant chemoradiotherapy with docetaxel and 5-fluorouracil followed by esophagectomy to treat locally advanced esophageal cancer. Ann Thorac Surg 99:1887–1893

    Article  PubMed  Google Scholar 

  5. Wood MD, Zaki BI, Gordon SR et al (2013) Trimodality therapy for stage II–III carcinoma of the esophagus: a dose-ranging study of concurrent capecitabine, docetaxel, and thoracic radiotherapy. J Thorac Oncol 8:487–494

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Berger AC, Farma J, Scott WJ et al (2005) Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 23:4330–4337

    Article  PubMed  Google Scholar 

  7. Alnaji RM, Du W, Gabriel E et al (2016) Pathologic complete response is an independent predictor of improved survival following neoadjuvant chemoradiation for esophageal adenocarcinoma. J Gastrointest Surg 20:1541–1546

    Article  PubMed  Google Scholar 

  8. Hamai Y, Hihara J, Emi M et al (2016) Ability of fluorine-18 fluorodeoxyglucose positron emission tomography to predict outcomes of neoadjuvant chemoradiotherapy followed by surgical treatment for esophageal squamous cell carcinoma. Ann Thorac Surg 102:1132–1139

    Article  PubMed  Google Scholar 

  9. Hamai Y, Hihara J, Taomoto J et al (2014) Hemoglobin level influences tumor response and survival after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma. World J Surg 38:2046–2051. doi:10.1007/s00268-014-2486-2

    Article  PubMed  Google Scholar 

  10. Shapiro J, Biermann K, van Klaveren D et al (2017) Prognostic value of pretreatment pathological tumor extent in patients treated with neoadjuvant chemoradiotherapy plus surgery for esophageal or junctional cancer. Ann Surg 265:356–362

    Article  PubMed  Google Scholar 

  11. Wen J, Luo K, Liu H et al (2016) MiRNA expression analysis of pretreatment biopsies predicts the pathological response of esophageal squamous cell carcinomas to neoadjuvant chemoradiotherapy. Ann Surg 263:942–948

    Article  PubMed  Google Scholar 

  12. Wen J, Yang H, Liu MZ et al (2014) Gene expression analysis of pretreatment biopsies predicts the pathological response of esophageal squamous cell carcinomas to neo-chemoradiotherapy. Ann Oncol 25:1769–1774

    Article  CAS  PubMed  Google Scholar 

  13. Arnold M, Soerjomataram I, Ferlay J et al (2015) Global incidence of oesophageal cancer by histological subtype in 2012. Gut 64:381–387

    Article  PubMed  Google Scholar 

  14. Agrawal N, Jiao Y, Bettegowda C et al (2012) Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. Cancer Discov 2:899–905

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Ohashi S, Miyamoto S, Kikuchi O et al (2015) Recent advances from basic and clinical studies of esophageal squamous cell carcinoma. Gastroenterology 149:1700–1715

    Article  PubMed  Google Scholar 

  16. Koshy M, Greenwald BD, Hausner P et al (2011) Outcomes after trimodality therapy for esophageal cancer: the impact of histology on failure patterns. Am J Clin Oncol 34:259–264

    Article  PubMed  Google Scholar 

  17. Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655

    Article  CAS  PubMed  Google Scholar 

  18. Sobin LH, Gospodarowicz MK, Wittekind C, International Union against Cancer (2010) TNM classification of malignant tumours, 7th edn. Wiley-Blackwell, Chichester

    Google Scholar 

  19. Hamai Y, Hihara J, Taomoto J et al (2015) Effects of neoadjuvant chemoradiotherapy on postoperative morbidity and mortality associated with esophageal cancer. Dis Esophagus 28:358–364

    Article  CAS  PubMed  Google Scholar 

  20. Emi M, Hihara J, Hamai Y et al (2012) Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil for esophageal cancer. Cancer Chemother Pharmacol 69:1499–1505

    Article  CAS  PubMed  Google Scholar 

  21. Miyata H, Yamasaki M, Takiguchi S et al (2010) Pre- and post-therapy nodal status equally affects survival of patients with oesophageal squamous cell carcinoma receiving preoperative chemoradiation. Oncol Rep 23:1331–1337

    Article  PubMed  Google Scholar 

  22. Akutsu Y, Shuto K, Kono T et al (2012) The number of pathologic lymph nodes involved is still a significant prognostic factor even after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma. J Surg Oncol 105:756–760

    Article  PubMed  Google Scholar 

  23. Chao YK, Chen HS, Wang BY et al (2016) Prognosis of patients with pathologic T0N+ esophageal squamous cell carcinoma after chemoradiotherapy and surgical resection: results from a nationwide study. Ann Thorac Surg 101:1897–1902

    Article  PubMed  Google Scholar 

  24. Jung HA, Adenis A, Lee J et al (2013) Nomogram to predict treatment outcome of fluoropyrimidine/platinum-based chemotherapy in metastatic esophageal squamous cell carcinoma. Cancer Res Treat 45:285–294

    Article  PubMed  PubMed Central  Google Scholar 

  25. Clavier JB, Antoni D, Atlani D et al (2014) Baseline nutritional status is prognostic factor after definitive radiochemotherapy for esophageal cancer. Dis Esophagus 27:560–567

    Article  PubMed  Google Scholar 

  26. Siersema PD, van Hillegersberg R (2008) Treatment of locally advanced esophageal cancer with surgery and chemoradiation. Curr Opin Gastroenterol 24:535–540

    Article  PubMed  Google Scholar 

  27. Stiles BM, Salzler GG, Nasar A et al (2015) Clinical predictors of early cancer-related mortality following neoadjuvant therapy and oesophagectomy. Eur J Cardiothorac Surg 48:455–460

    Article  PubMed  Google Scholar 

  28. Brescia AA, Broderick SR, Crabtree TD et al (2016) Adjuvant therapy for positive nodes after induction therapy and resection of esophageal cancer. Ann Thorac Surg 101:200–208

    Article  PubMed  Google Scholar 

  29. Hsu HY, Chao YK, Hsieh CH et al (2016) Postoperative adjuvant therapy improves survival in pathologic nonresponders after neoadjuvant chemoradiation for esophageal squamous cell carcinoma: a propensity-matched analysis. Ann Thorac Surg 102:1687–1693

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Yoichi Hamai.

Ethics declarations

Conflict of interest

The authors have no commercial support or conflicts of interest to disclose.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hamai, Y., Hihara, J., Emi, M. et al. Evaluation of Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgery. World J Surg 42, 1496–1505 (2018).

Download citation

  • Published:

  • Issue Date:

  • DOI: